Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 01, 2005 (Vol. 25, No. 1)

Vioxx and Celebrex Bring Heat to the FDA

Calls Made for Agency to Review its Operations

  • The FDA remains firm that it did nothing wrong in its post-marketing review of Vioxx. Critics are equally adamant, citing a systemic failure within the FDA that allowed a medication to remain on the market despite studies indicating the need for serious caution. Congress and the Institute of Medicine ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.